COPD and tobacco smoke

Chronic obstructive pulmonary disease (COPD) is a chronic inflammation of the airways, including the parenchyma and the pulmonary vasculature. The burden of COPD is increasing around the world in terms of morbidity and mortality in adult population. Active smoking is a major risk factor for COPD, al...

Full description

Bibliographic Details
Main Author: M. Bartal
Format: Article
Language:English
Published: PAGEPress Publications 2005-12-01
Series:Monaldi Archives for Chest Disease
Subjects:
Online Access:https://www.monaldi-archives.org/index.php/macd/article/view/623
id doaj-fdf8d40fd40443678b90eafa9faf1e87
record_format Article
spelling doaj-fdf8d40fd40443678b90eafa9faf1e872020-11-24T21:33:24ZengPAGEPress PublicationsMonaldi Archives for Chest Disease1122-06432532-52642005-12-0163410.4081/monaldi.2005.623COPD and tobacco smokeM. Bartal0President of the Moroccan Society of Allergology and Clinical Immunology, CasablancaChronic obstructive pulmonary disease (COPD) is a chronic inflammation of the airways, including the parenchyma and the pulmonary vasculature. The burden of COPD is increasing around the world in terms of morbidity and mortality in adult population. Active smoking is a major risk factor for COPD, although there is individual susceptibility to the effects of tobacco smoke. This variability could result from host as well as environmental factors. Even passive smoking in early childhood as well as intrauterine exposure could pave the way for COPD. Tobacco smoke induces a specific, persistent inflammation, different from that of asthma. Three other processes accompany and interact with inflammation: imbalance of both the proteases- antiproteases, the oxidants-antioxidants, and improper repair mechanisms. These processes respectively lead to mucus hypersecretion and alveol wall destruction, dysfunction and death of biological molecules, damage to the extracellular matrix and pulmonary fibrosis with adventitial, submucosal and smooth muscle thickening. The earlier the smoke exposure, the greater the level of decline in lung function. Combined mucus hypersecretion, reduced clearance, and impairment of the lung defence mechanisms explain why COPD patients even with stable condition, carry potential respiratory pathogens in significant concentration, paving the way for infection and acute exacerbations of COPD. Every additional exacerbation in a smoker deteriorate more the lung function. Fortunately, smoking cessation, which is a part of the respiratory rehabilitation could reduce the number of hospitalisations and the decline of lung function, and thus reduce the management cost of the disease and improve the quality of life. The earlier the quitting, the better the improvement of FEV1. “Smoking cessation is the single effective and cost effective way to reduce exposure to COPD risk factors” (GOLD, evidence A).https://www.monaldi-archives.org/index.php/macd/article/view/623TobaccosmokingCOPDlung functionsmoking cessation
collection DOAJ
language English
format Article
sources DOAJ
author M. Bartal
spellingShingle M. Bartal
COPD and tobacco smoke
Monaldi Archives for Chest Disease
Tobacco
smoking
COPD
lung function
smoking cessation
author_facet M. Bartal
author_sort M. Bartal
title COPD and tobacco smoke
title_short COPD and tobacco smoke
title_full COPD and tobacco smoke
title_fullStr COPD and tobacco smoke
title_full_unstemmed COPD and tobacco smoke
title_sort copd and tobacco smoke
publisher PAGEPress Publications
series Monaldi Archives for Chest Disease
issn 1122-0643
2532-5264
publishDate 2005-12-01
description Chronic obstructive pulmonary disease (COPD) is a chronic inflammation of the airways, including the parenchyma and the pulmonary vasculature. The burden of COPD is increasing around the world in terms of morbidity and mortality in adult population. Active smoking is a major risk factor for COPD, although there is individual susceptibility to the effects of tobacco smoke. This variability could result from host as well as environmental factors. Even passive smoking in early childhood as well as intrauterine exposure could pave the way for COPD. Tobacco smoke induces a specific, persistent inflammation, different from that of asthma. Three other processes accompany and interact with inflammation: imbalance of both the proteases- antiproteases, the oxidants-antioxidants, and improper repair mechanisms. These processes respectively lead to mucus hypersecretion and alveol wall destruction, dysfunction and death of biological molecules, damage to the extracellular matrix and pulmonary fibrosis with adventitial, submucosal and smooth muscle thickening. The earlier the smoke exposure, the greater the level of decline in lung function. Combined mucus hypersecretion, reduced clearance, and impairment of the lung defence mechanisms explain why COPD patients even with stable condition, carry potential respiratory pathogens in significant concentration, paving the way for infection and acute exacerbations of COPD. Every additional exacerbation in a smoker deteriorate more the lung function. Fortunately, smoking cessation, which is a part of the respiratory rehabilitation could reduce the number of hospitalisations and the decline of lung function, and thus reduce the management cost of the disease and improve the quality of life. The earlier the quitting, the better the improvement of FEV1. “Smoking cessation is the single effective and cost effective way to reduce exposure to COPD risk factors” (GOLD, evidence A).
topic Tobacco
smoking
COPD
lung function
smoking cessation
url https://www.monaldi-archives.org/index.php/macd/article/view/623
work_keys_str_mv AT mbartal copdandtobaccosmoke
_version_ 1725953458610110464